title: [Osteoporosis treatment with biphosphonates: Approaches to care reality].
abstract: OBJECTIVE
  Osteoporosis predominantly affects menopausal women and has a significant morbidity expressed as fractures. The study aimed to describe the types of bisphosphonates used to treat osteoporosis in post-menopausal women and to establish how treatment non-compliance affects the fracture rate.
  
  
  METHODS
  Retrospective cohort study of women on active treatment with bisphosphonates for the past five years.
  
  
  METHODS
  Utebo Health Centre (Zaragoza) (16,000 inhabitants) with a general medical quota of 1,890 patients).
  
  
  METHODS
  A total of 129 women who were on active treatment with bisphosphonates for five years were included.
  
  
  METHODS
  The distribution by drug was analysed, as well as the percentage of women who did not comply with the treatment correctly and any identified fractures.
  
  
  RESULTS
  A total of 129 women on treatment were identified (13.0% of all women patients): alendronic acid (45.7%), ibandronic acid (21.7%), risedronic acid (19.4%) and alendronic acid plus cholecalciferol (13,2%). 19.4% of women stopped their treatment after at least 3 months. Thirteen hip fractures were identified.
  
  
  CONCLUSIONS
  The overall treatment compliance was 80.6%, Depending on the type of bisphosphonate: alendronic acid plus cholecalciferol (88.2%), risedronic acid (88.0%), alendronic acid (78.0%), ibandronic acid (75.0%). The incidence of hip fractures was similar incidence to that observed with respect to non-compliance to treatment. Lack of therapeutic compliance is common in menopausal women, and measures should be promoted to increase effectiveness as well as to make patients aware of the importance of continuing treatment.
authors.affiliation: Urgencias, Hospital Royo Villanova, Zaragoza, España.
authors.forename: Angel
authors.initials: A
authors.lastname: Vicente Molinero
authors.forename: Salvador
authors.initials: S
authors.lastname: Lou Arnal
authors.forename: Esteban
authors.initials: E
authors.lastname: Medina Orgaz
authors.forename: Sergio
authors.initials: S
authors.lastname: Muñoz Jacobo
authors.forename: José
authors.initials: J
authors.lastname: Antonio Ibáñez Estrella
mesh_terms: D015331:Cohort Studies; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008593:Menopause; D010024:Osteoporosis / Q000188:drug therapy*; D058866:Osteoporotic Fractures / Q000517:prevention & control; D012189:Retrospective Studies; D016903:Drug Monitoring
chemical_list: D004164:Diphosphonates